I was intrigued to see the recent paper by Ghazizadeh-Hashemi et al - "Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial" - with its abstract reading: "Experimental studies provide evidence for antidepressant effects of Palmitoylethanolamide (PEA) in animal models of depression.  We aimed to evaluate the efficacy and tolerability of PEA add-on therapy in treatment of patients with major depressive disorder (MDD).  Methods In a randomized double-blind, and placebo-controlled study, 58 patients with MDD (DSM-5) and Hamilton Depression Rating Scale (HAM-D) score ≥ 19 were randomized to receive either 600 mg twice daily Palmitoylethanolamide or placebo in addition to citalopram for six weeks ...